Results 241 to 250 of about 19,810 (255)

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

Cancers, 2022
Niloefar Ahmadi Bidakhvidi, Karolien Goffin, Jeroen Dekervel   +2 more
exaly  

Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study

Scandinavian Journal of Gastroenterology, 2021
Simon Mark Dahl Jørgensen, Henning Grønbæk   +1 more
exaly  

Treatment of neuroendocrine tumours with 177 Lu‐peptide receptor radionuclide therapy: Challenging clinical scenarios and their management

Journal of Neuroendocrinology, 2022
Shaunak, CHRISTOS TOUMPANAKIS, Martyn Caplin   +2 more
exaly  

<p>Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights</p>

OncoTargets and Therapy, 2020
Jason S Starr, Mohamad Bassam Sonbol, Akash Sharma   +2 more
exaly  

A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

Cancers, 2022
Tessa Brabander, Julie Nonnekens, Johannes Hofland   +2 more
exaly  

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward

Current Topics in Medicinal Chemistry, 2020
Julie Nonnekens
exaly  

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

European Journal of Cancer, 2016
Samer Ezziddin, Alexander R Haug, Matthias Miederer   +2 more
exaly  

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Pharmaceuticals, 2019
Ute Hennrich, Klaus Kopka
exaly  

Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours

Cancer Treatment Reviews, 2018
Jorge Barriuso, Ana, Jaume Capdevila
exaly  

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

European Journal of Nuclear Medicine and Molecular Imaging, 2013
James R Howe
exaly